• About
  • Policies
  • What is openaccess
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells

      Thumbnail
      View / Download
      492.9 Kb
      Author
      Ghasemi, M.
      Erturk, M.
      Buruk, K.
      Sonmez, M.
      Date
      2013
      Source Title
      Cytotherapy
      Print ISSN
      14653249
      Volume
      15
      Issue
      3
      Pages
      352 - 361
      Language
      English
      Type
      Article
      Item Usage Stats
      113
      views
      114
      downloads
      Abstract
      Background aims. Dendritic cells (DCs) are the most potent antigen presenting cells of the immune system and have been under intense study with regard to their use in immunotherapy against cancer and infectious disease agents. In the present study, DCs were employed to assess their value in protection against live virus challenge in an experimental model using lethal and latent herpes simplex virus (HSV) infection in Balb/c mice. Methods. DCs obtained ex vivo in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4 were loaded with HSV-1 proteins (DC/HSV-1 vaccine). Groups of mice were vaccinated twice, 7 days apart, via subcutaneous, intraperitoneal or intramuscular routes with DC/HSV-1 and with mock (DC without virus protein) and positive (alum adjuvanted HSV-1 proteins [HSV-1/ALH]) control vaccines. After measuring anti-HSV-1 antibody levels in blood samples, mice were given live HSV-1 intraperitoneally or via ear pinna to assess the protection level of the vaccines with respect to lethal or latent infection challenge. Results. Intramuscular, but not subcutaneous or intraperitoneal, administration of DC/HSV-1 vaccine provided complete protection against lethal challenge and establishment of latent infection as assessed by death and virus recovery from the trigeminal ganglia. It was also shown that the immunity was not associated with antibody production because DC/HSV-1 vaccine, as opposed to HSV-1/ALH vaccine, produced very little, if any, HSV-1-specific antibody. Conclusions. Overall, our results may have some impact on the design of vaccines against genital HSV as well as chronic viral infections such as hepatitis B virus, hepatitis C virus and human immunodeficiency virus. © 2013, International Society for Cellular Therapy.
      Keywords
      Dendritic cells
      Herpes simplex virus
      Mice
      Vaccine
      dendritic cell vaccine
      granulocyte macrophage colony stimulating factor
      herpes simplex vaccine
      interleukin 4
      animal cell
      animal experiment
      animal model
      antibody production
      article
      controlled study
      ex vivo study
      herpes simplex
      immunization
      mouse
      nonhuman
      priority journal
      treatment response
      trigeminus ganglion
      virus immunity
      Animals
      Antibodies, Viral
      Dendritic Cells
      Granulocyte-Macrophage Colony-Stimulating Factor
      Herpes Simplex
      Herpes Simplex Virus Vaccines
      Humans
      Immunotherapy
      Interleukin-4
      Mice
      Simplexvirus
      Viral Envelope Proteins
      Permalink
      http://hdl.handle.net/11693/21049
      Published Version (Please cite this version)
      http://dx.doi.org/10.1016/j.jcyt.2012.11.012
      Collections
      • Department of Molecular Biology and Genetics 426
      Show full item record

      Related items

      Showing items related by title, author, creator and subject.

      • Thumbnail

        Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade 

        Lotem, M.; Merims, S.; Frank, S.; Hamburger, T.; Nissan, A.; Kadouri, L.; Cohen, J.; Straussman, R.; Eisenberg, G.; Frankenburg, S.; Carmon, E.; Alaiyan, B.; Shneibaum, S.; Ayyildiz, Z. O.; Isbilen, M.; Senses, K. M.; Ron, I.; Steinberg, H.; Smith, Y.; Shiloni, E.; Gure, A. O.; Peretz, T. (Hindawi Limited, 2016)
        Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease ...
      • Thumbnail

        Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development 

        Bayyurt, B.; Tincer, G.; Almacioglu, K.; Alpdundar, E.; Gursel, M.; Gursel, I. (Elsevier B.V., 2017)
        Nucleic acid-based Toll-like receptor (TLR) ligands are promising adjuvants and immunotherapeutic agents. Combination of TLR ligands potentiates immune response by providing synergistic immune activity via triggering ...
      • Thumbnail

        Biosystems engineering of prokaryotes with tumor-killing capacities 

        Kalyoncu, E.; Olmez, T. T.; Ozkan, A. D.; Sarioglu, O. F. (Bentham Science Publishers Ltd., 2016)
        Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic ...

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartments

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 1771
      Copyright © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy